Allysta Pharmaceuticals, Inc. Announces Initiation of Dosing in OASIS-1 Phase 2b/3 Clinical Trial (ALY688-301 Study) Evaluating the Efficacy and Safety of ALY688 Ophthalmic Solution in Dry Eye
ALY688 Ophthalmic Solution advancing to pivotal studies based upon promising clinical safety and efficacy dataMulticenter US study to enroll subjects...